Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis

Eur Respir J. 2018 Jun 7;51(6):1702457. doi: 10.1183/13993003.02457-2017. Print 2018 Jun.

Authors

Cormac McCarthy^{1

2

3}, John J Brewington², Beth Harkness⁴, John P Clancy², Bruce C Trapnell^{1

2

3}

Affiliations

¹ Translational Pulmonary Science Center, Division of Pulmonary Biology, Children's Hospital Medical Center, Cincinnati, OH, USA.
² Division of Pulmonary Medicine, Children's Hospital Medical Center, Cincinnati, OH, USA.
³ Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
⁴ Children's National Medical Center, Washington, DC, USA.

PMID: 29563174
DOI: 10.1183/13993003.02457-2017

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aminophenols / therapeutic use
Aminopyridines / therapeutic use
Benzodioxoles / therapeutic use
Cystic Fibrosis / drug therapy
Cystic Fibrosis / genetics*
Cystic Fibrosis Transmembrane Conductance Regulator / agonists
Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
Humans
Male
Mutation
Precision Medicine
Quinolones / therapeutic use

Substances

Aminophenols
Aminopyridines
Benzodioxoles
CFTR protein, human
Quinolones
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor
lumacaftor